The market for peptide therapies is predicted to grow at an excellent CAGR of 10.8% from 2023 to 2033, from a current estimated value of US$ 38.0 billion to US$ 106.0 billion.
Due to a variety of variables, including an increase in the aged population, an increase in the frequency of chronic diseases, and a rise in patient knowledge of peptide therapies breakthroughs, the market for peptide therapeutics is predicted to expand. The rise in product creation and technical advancements is another significant market trend that is likely to boost expansion during the forecast period.
Key Market Movements
Due to the adaptation of modern and unhealthy lifestyles, there is a clear increasing trend in metabolic illnesses such as diabetes and obesity, as well as an increase in cardiovascular diseases and cancer. As a result, the aforementioned reasons are driving the peptide therapies market opportunity.
The limited bioavailability of peptides, as well as the high cost of therapeutic development, is projected to stifle market expansion. Conversely, the significant growth potential for the oral peptide therapies market as a result of rising purchasing power in emerging nations represents a lucrative opportunity for peptide therapeutics market expansion.
Get Latest Sample Copy@ https://www.futuremarketinsights.com/reports/sample/rep-gb-1038
Cancer Segment to Exhibit the Fastest CAGR
Due to their high selectivity, discernment, tiny sizes, simplicity of modification, and high biocompatibility, peptides offer promising prospects in cancer-targeted medication delivery. The increasing prevalence of cancer worldwide, as well as the increasing prescription of peptide therapies for cancer therapy, is the primary factors driving this segment’s domination.
The high prevalence of cancer cases worldwide is likely to play a significant influence on the segment’s growth throughout the forecast period. The greater awareness among patients and healthcare professionals about the negative consequences of chemotherapy and radiation therapy is a crucial factor driving the increased emphasis on alternative medicines such as peptide-based drugs.
Regional Outlook
Asia Pacific is Envisioned to be Economically Viable
North America accounted for the majority of the global peptide therapeutics market share and is expected to continue dominating over the projected period. This is due to technological breakthroughs in peptide therapy techniques, the integration of advanced hardware and software processes in peptide therapeutics devices, the presence of important market participants, and the region’s robust hospital infrastructure.
Asia Pacific is expected to grow significantly, owing to an increase in the region’s geriatric population, the expansion of healthcare infrastructure, and an increase in investment projects.
Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-1038
Key Takeaways
- By application, the cancer segment of the peptide therapeutics market is to have a CAGR of 10.6% during the forecast period.
- During the projection period, the US peptide therapeutics market would develop at a CAGR of 11%.
- The parenteral route segment of the peptide therapeutics market is forecast to expand at a CAGR of 10.8% during the projected period.
- The market for peptide therapeutics in the UK is anticipated to expand at a CAGR of 9.8% during the anticipated time frame.
- During the projection period, the German peptide therapeutics market would develop at a CAGR of 9.9%.
- Over the course of the projected period, the China market for peptide therapeutics is expected to expand at a CAGR of 11.1%.
- During the projected period, the India market for peptide therapeutics is expected to expand at a CAGR of 11.7%.
Competitive Environment
There are several significant participants in the moderately competitive peptide therapeutics market. Eli Lilly and Company, Pfizer Inc., Amgen Inc., Bristol-Myers Squibb Company, EVER NEURO PHARMA GmbH, Takeda Pharmaceutical Company Limited, and many others are a few of the businesses now ruling the market.
For the international expansion of their product portfolios, the leading players are engaged in strategic alliances such as acquisitions and collaborations, coupled with research efforts.
Latest Developments
Partnership
A strategic research partnership between Nimble Therapeutics and Incyte was established in September 2021 to explore the development of future innovative peptide therapeutics.
Licensing
The decision to licence out its peptide-based novel chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare requirements of the people was made by ISSAR Pharmaceuticals in May 2021, making it affordable
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-1038
Key Segments
By Product:
- Workflow Management Solution
- Asset Management Solution
- Bed Management Solution
- Quality Patient Care Solution
- Real Time Locating System (RTLS)
- Event Driven Solutions
- Online Registration Solution
- Attendance Management Tools
- Event Driven Patient Tracking
- Others
By Application:
- Standalone Solutions
- Integrated Solutions
By Delivery Mode:
- On Premise
- Cloud-Based
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
